DTP-HepB-Polio-Hib vaccine - Sanofi

Drug Profile

DTP-HepB-Polio-Hib vaccine - Sanofi

Alternative Names: Shan6

Latest Information Update: 27 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi
  • Developer Shantha Biotechnics
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 08 Feb 2017 Phase-II clinical trials in Haemophilus infections, Hepatitis B, Diphtheria, Pertussis, Poliomyelitis and Tetanus(Prevention) in France (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top